Dr. Robert Zipursky is an associate scientist with the Schizophrenia Division at CAMH and a professor of psychiatry at the University of Toronto. He established the First Episode Psychosis Program at the Clarke Institute of Psychiatry/CAMH in 1992, a clinical research program devoted to studying the neurobiology, treatment and course of schizophrenia. Dr. Zipursky was appointed as clinical director of the Schizophrenia Division at CAMH in 1998 and as Tapscott Chair in Schizophrenia Studies at the University of Toronto in 2000. In 2007, Dr. Zipursky was appointed as Chair of the Department of Psychiatry and Behavioural Neurosciences at McMaster University. He returned to the University of Toronto and CAMH in 2018. He is the recipient of the John Cleghorn Memorial Award for Excellence and Leadership in Clinical Research from the Canadian Psychiatric Association and the APA/Kempf Fund Award for Research Development in Psychobiological Psychiatry from the American Psychiatric Association.
Areas of Research
Dr. Zipursky’s research using MRI identified widespread difference in brain gray matter volumes in schizophrenia and their association with treatment response, cognitive deficits and medication exposure. His research in first episode schizophrenia has contributed to our understanding that schizophrenia is highly responsive to low doses of antipsychotic medication and can remain well controlled with long-term treatment. His current research focuses on defining the minimum effective doses of antipsychotic medication required for relapse prevention in schizophrenia.
Publications
View Dr. Zipursky's publications on Google Scholar.